CODIAK BIOSCIENCES
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
CODIAK BIOSCIENCES
Industry:
Biotechnology Medical Therapeutics
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.codiakbio.com
Total Employee:
101+
Status:
Active
Contact:
(617) 949-4100
Email Addresses:
[email protected]
Total Funding:
237.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Euro IPv6 PostalAddress Schema Unified Layer Comcast Akamai Hosted BlueHost
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Amunix
Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics.
Global Blood Therapeutics
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Coalition for Epidemic Preparedness Innovations
Coalition for Epidemic Preparedness Innovations investment in Post-IPO Equity - Codiak Biosciences
Yukon Partners
Yukon Partners investment in Series C - Codiak Biosciences
Qatar Investment Authority
Qatar Investment Authority investment in Series C - Codiak Biosciences
Alexandria Venture Investments
Alexandria Venture Investments investment in Series C - Codiak Biosciences
ARCH Venture Partners
ARCH Venture Partners investment in Series C - Codiak Biosciences
EcoR1 Capital
EcoR1 Capital investment in Series C - Codiak Biosciences
Casdin Capital
Casdin Capital investment in Series C - Codiak Biosciences
Alaska Permanent Fund
Alaska Permanent Fund investment in Series C - Codiak Biosciences
Sirona Capital
Sirona Capital investment in Series C - Codiak Biosciences
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Codiak Biosciences
Key Employee Changes
Official Site Inspections
http://www.codiakbio.com Semrush global rank: 4.52 M Semrush visits lastest month: 2.35 K
- Host name: msp-a100-1135.arcusvps.net
- IP address: 162.247.143.135
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Codiak Biosciences"
Codiak Biosciences - Crunchbase Company Profile
Contact Email [email protected] Phone Number (617) 949-4100 Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with …See details»
Codiak Biosciences - VentureRadar
Codiak is building a world-class team and has generated, acquired and licensed foundational intellectual property to enable the development of products that capitalize on the unique …See details»
Codiak BioSciences, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Codiak BioSciences, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Codiak Biosciences - Craft
Aug 19, 2024 Codiak Biosciences is a biopharmaceutical company focused on the development of exosome-based therapeutics. By leveraging the biology of exosomes as natural intercellular …See details»
Codiak BioSciences - PitchBook
Codiak BioSciences General Information Description. Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases …See details»
Codiak Biosciences Company Profile: Overview and Full News …
Codiak Biosciences is a biotechnology company based in California that specializes in the development of exosome-based therapeutics. Exosomes are small vesicles that play a crucial …See details»
Codiak BioSciences - Overview, News & Similar companies
Jan 24, 2023 Codiak BioSciences contact info: Phone number: (617) 949-4100 Website: www.codiakbio.com What does Codiak BioSciences do? Codiak is a clinical-stage …See details»
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing …
Nov 2, 2021 Doug Williams, PhD, CEO, Codiak BioSciences, added: “Creating an exosome manufacturing Center of Excellence with Lonza, a leading global contract development …See details»
Codiak Biosciences CEO and Key Executive Team | Craft.co
Codiak Biosciences's President, Chief Executive Officer, Director is Douglas E. Williams. Other executives include Anne-Virginie Eggimann, Director; Linda C. Bain, Chief Financial Officer …See details»
Codiak BioSciences - Company info. interviews, news
Dec 29, 2022 15 Biopharma Research Trends to Watch in 2022 Dec. 29, 2022 Table of contents: mRNA vaccines and RNA therapies Epitranscriptomics Targeting RNA with small molecules Deep learning and big data in drug …See details»
CEPI partners with Codiak BioSciences to develop broadly …
Jul 5, 2022 Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, Codiak said: "We are incredibly honored to be recognized by an organization as well-respected as CEPI and grateful …See details»
Codiak BioSciences - Golden
On November 27, 2017 Codiak BioSciences completed their series C funding round with $76.5 million in capital from Sirona Capital, Qatar Investment Authority, Flagship Pioneering, Fidelity …See details»
Working At Codiak BioSciences: Company Overview and Culture
Mar 14, 2024 www.codiakbio.com. Organization Type. Public. Social Media. Codiak Biosciences is developing exosomes, natural vesicles that mediate inter-cellular communication, as both a …See details»
Codiak Biosciences files for bankruptcy - Fierce Biotech
Mar 27, 2023 The first cracks appeared back in August, when Codiak laid off over a third of its staff—leaving it with 53 full-time employees—and paused plans to launch phase 2 studies for …See details»
Codiak Biosciences (USA) Funding: $257.4M - Medical Startups
Jan 9, 2025 Codiak Biosciences is developing multiple platforms for both therapeutic and diagnostic applications based on a growing appreciation for exosome...See details»
Codiak BioSciences Announces Program Reprioritization and
Aug 30, 2022 Codiak BioSciences has aligned the organization to reflect its smaller, refocused pipeline. The Company’s workforce will be reduced by 37%, to 53 full-time employees, to …See details»
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing …
Nov 2, 2021 Lonza to acquire and operate Codiak's Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipelineLonza and Codiak to establish a Center of …See details»
Codiak BioSciences Inc. - Cruelty Free Investing
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the …See details»
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing
Feb 11, 2021 Doug Williams, PhD, CEO, Codiak BioSciences, added: “Creating an exosome manufacturing Center of Excellence with Lonza, a leading global contract development …See details»
Codiak BioSciences to Pursue Asset Sale through Voluntary …
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of …See details»